  It isn't easy to stand up and face the challenge of overcoming opioid dependence. But you've already done one of the hardest parts—getting started. Knowing more about what lies ahead can help you stay focused on success as you move forward. Remember, reducing withdrawal symptoms and cravings is only part of your treatment. The real goal of your treatment is overcoming opioid dependence—a chronic medical condition that takes time to address. Treatment is usually approached in three phases:
Treatment and support work best together. That's why the Here to Help™ Program gives you the extra support you might need to manage your treatment—including useful tools and resources, your own personal Care Coach, and help finding a counseling option that's right for you. Get the most out of your treatment:
Over the next days, weeks, and months, as you work with your treatment team to reach your goals, remember—we're Here to Help. Take care,  866-973-HERE (4373) | ||||||||||||||||||||||||||
|
Unsubscribe | Privacy Promise | Terms of Use | Prescribing Information This communication is sponsored by Reckitt Benckiser Pharmaceuticals Inc. and intended for residents of the United States. © 2009 Reckitt Benckiser Pharmaceuticals Inc. SUBOXONE® and SUBUTEX® are registered trademarks of Reckitt Benckiser Pharmaceuticals Inc. ("Reckitt Benckiser") or its affiliated companies. Here to Help™ is a trademark of Reckitt Benckiser Pharmaceuticals Inc. This information in this e-mail is provided for educational and informational purposes only and is not intended as a substitute for direct consultation with a qualified mental health professional.  
Important Safety Information
SUBOXONE® (buprenorphine HCl/naloxone HCl dihydrate sublingual tablets) (CIII) is indicated for the treatment of opioid dependence. It is extremely dangerous to take benzodiazepines or other depressants while taking SUBOXONE. A serious overdose and death may occur if benzodiazepines, sedatives, tranquilizers, antidepressants, or alcohol are taken at the same time as SUBOXONE. SUBOXONE has potential for abuse and produces dependence of the opioid type, with a milder withdrawal syndrome than full agonists. Cytolytic hepatitis and hepatitis with jaundice have been observed in the addicted population receiving buprenorphine. Allergic reactions including bronchospasm, angioneurotic edema, and anaphylactic shock have been reported in patients taking buprenorphine. There are no adequate and well-controlled studies of SUBOXONE (a Category C medication) in pregnancy. Caution should be exercised when driving cars or operating machinery. Always store buprenorphine-containing medications safely and out of the reach and sight of children. Destroy any unused medication appropriately. The most commonly reported adverse events with SUBOXONE include: headache (36%, placebo 22%), withdrawal syndrome (25%, placebo 37%), pain (22%, placebo 19%), insomnia (14%, placebo 16%), nausea (15%, placebo 11%), and constipation (12%, placebo 3%). Please see full Prescribing Information for a complete list. To report an adverse event caused by taking SUBOXONE, please call 1-877-782-6966. You are also encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Please see full US Prescribing Information for SUBOXONE. |